Search

Your search keyword '"DRANSFIELD, MARK T."' showing total 1,355 results
Start Over Author "DRANSFIELD, MARK T."
1,355 results on '"DRANSFIELD, MARK T."'

201. Pulmonary Artery Enlargement Is Associated with Exacerbations and Mortality in Ever-Smokers with Preserved Ratio Impaired Spirometry

Author

Wade, R. Chad, primary, Simmons, J. Patrick, additional, Boueiz, Adel, additional, Gregory, Andrew, additional, Wan, Emily S., additional, Regan, Elizabeth A., additional, Bhatt, Surya P., additional, Han, MeiLan K., additional, Bowler, Russell P., additional, Crapo, James D., additional, Silverman, Edwin K., additional, Washko, George R., additional, Dransfield, Mark T., additional, and Wells, J. Michael, additional

Published
2021
Full Text
View/download PDF

202. A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial

Author

Bafadhel, Mona, primary, Barnes, Neil, additional, Bourke, Stephen C., additional, Compton, Chris, additional, Criner, Gerard J., additional, Dransfield, Mark T., additional, Halpin, David M.G., additional, Han, MeiLan K., additional, Hartley, Benjamin, additional, Jones, C. Elaine, additional, Lange, Peter, additional, Lettis, Sally, additional, Lipson, David A., additional, Lomas, David A., additional, Martin, Neil, additional, Martinez, Fernando J., additional, Wise, Robert, additional, and Singh, Dave, additional

Published
2021
Full Text
View/download PDF

203. Association between Cardiorespiratory Fitness and Bronchiectasis at CT: A Long-term Population-based Study of Healthy Young Adults Aged 18–30 Years in the CARDIA Study

Author

Diaz, Alejandro A., primary, Colangelo, Laura A., additional, Okajima, Yuka, additional, Yen, Andrew, additional, Sala, Marc A., additional, Dransfield, Mark T., additional, Tino, Gregory, additional, Ross, James C., additional, San José Estépar, Raúl, additional, Washko, George R., additional, and Kalhan, Ravi, additional

Published
2021
Full Text
View/download PDF

204. Study protocol for a national cohort of adults focused on respiratory health: the American Lung Association Lung Health Cohort (ALA-LHC) Study

Author

Reyfman, Paul A, primary, Sugar, Elizabeth, additional, Hazucha, Heather, additional, Hixon, Jenny, additional, Reynolds, Curt, additional, Bose, Sonali, additional, Dransfield, Mark T, additional, Han, MeiLan K, additional, Estepar, Raul San Jose, additional, Rice, Mary B, additional, Washko, George R, additional, Carnethon, Mercedes, additional, and Kalhan, Ravi, additional

Published
2021
Full Text
View/download PDF

205. Discordant diagnostic criteria for pneumonia in COPD trials:a review

Author

Wise, Robert A., Bafadhel, Mona, Crim, Courtney, Criner, Gerard J., Day, Nicola C., Halpin, David M.G., Han, Mei Lan K., Lange, Peter, Lipson, David A., Martinez, Fernando J., Maselli, Diego J., Midwinter, Dawn, Singh, Dave, Zysman, Maeva, Dransfield, Mark T., Russell, Richard E.K., Wise, Robert A., Bafadhel, Mona, Crim, Courtney, Criner, Gerard J., Day, Nicola C., Halpin, David M.G., Han, Mei Lan K., Lange, Peter, Lipson, David A., Martinez, Fernando J., Maselli, Diego J., Midwinter, Dawn, Singh, Dave, Zysman, Maeva, Dransfield, Mark T., and Russell, Richard E.K.

Abstract

Inhaled corticosteroids (ICS) have a class effect of increasing pneumonia risk in patients with COPD. However, pneumonia incidence varies widely across clinical trials of ICS use in COPD. This review clarifies methodological differences in defining and recording pneumonia events in these trials and discusses factors that could contribute to the varying pneumonia incidence. Literature searches and screening yielded 40 relevant references for inclusion. Methods used to capture pneumonia events in these studies included investigator-reported pneumonia adverse events, standardised list of signs or symptoms, radiographic confirmation of suspected cases and/or confirmation by an independent clinical end-point committee. In general, more stringent pneumonia diagnosis criteria led to lower reported pneumonia incidence rates. In addition, studies varied in design and population characteristics, including exacerbation history and lung function, factors that probably contribute to the varying pneumonia incidence. As such, cross-trial comparisons are problematic. A minimal set of standardised criteria for diagnosis and reporting of pneumonia should be used in COPD studies, as well as reporting of patients' pneumonia history at baseline, to allow comparison of pneumonia rates between trials. Currently, within-trial comparison of ICS-containing versus non-ICS-containing treatments is the appropriate method to assess the influence of ICS on pneumonia incidence.

Published
2021

206. InforMing the PAthway of COPD Treatment (IMPACT) trial:fibrinogen levels predict risk of moderate or severe exacerbations

Author

Singh, Dave, Criner, Gerard J., Dransfield, Mark T., Halpin, David M.G., Han, Mei Lan K., Lange, Peter, Lettis, Sally, Lipson, David A., Mannino, David, Martin, Neil, Martinez, Fernando J., Miller, Bruce E., Wise, Robert, Zhu, Chang Qing, Lomas, David, Singh, Dave, Criner, Gerard J., Dransfield, Mark T., Halpin, David M.G., Han, Mei Lan K., Lange, Peter, Lettis, Sally, Lipson, David A., Mannino, David, Martin, Neil, Martinez, Fernando J., Miller, Bruce E., Wise, Robert, Zhu, Chang Qing, and Lomas, David

Abstract

Background: Fibrinogen is the first qualified prognostic/predictive biomarker for exacerbations in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial investigated fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI and UMEC/VI in patients with symptomatic COPD at risk of exacerbations. This analysis used IMPACT trial data to examine the relationship between fibrinogen levels and exacerbation outcomes in patients with COPD. Methods: 8094 patients with a fibrinogen assessment at Week 16 were included, baseline fibrinogen data were not measured. Post hoc analyses were performed by fibrinogen quartiles and by 3.5 g/L threshold. Endpoints included on-treatment exacerbations and adverse events of special interest (AESIs). Results: Rates of moderate, moderate/severe, and severe exacerbations were higher in the highest versus lowest fibrinogen quartile (0.75, 0.92 and 0.15 vs 0.67, 0.79 and 0.10, respectively). The rate ratios (95% confidence interval [CI]) for exacerbations in patients with fibrinogen levels ≥ 3.5 g/L versus those with fibrinogen levels < 3.5 g/L were 1.03 (0.95, 1.11) for moderate exacerbations, 1.08 (1.00, 1.15) for moderate/severe exacerbations, and 1.30 (1.10, 1.54) for severe exacerbations. There was an increased risk of moderate/severe exacerbation (hazard ratio [95% CI]: highest vs lowest quartile 1.16 [1.04, 1.228]; ≥ 3.5 g/L vs < 3.5 g/L: 1.09 [1.00, 1.16]) and severe exacerbation (1.35 [1.09, 1.69]; 1.27 [1.08, 1.47], respectively) with increasing fibrinogen level. Cardiovascular AESIs were highest in patients in the highest fibrinogen quartile. Conclusions: Rate and risk of exacerbations was higher in patients with higher fibrinogen levels. This supports the validity of fibrinogen as a predictive biomarker for COPD exacerbations, and highlights the potential use of fibrinogen as an enrichment strategy in trials examining exacerbation outcomes. Trial registration: NCT02164513

Published
2021

207. A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial

Author

Bafadhel, Mona, Barnes, Neil, Bourke, Stephen C., Compton, Chris, Criner, Gerard J., Dransfield, Mark T., Halpin, David M.G., Han, Mei Lan K., Hartley, Benjamin, Jones, C. Elaine, Lange, Peter, Lettis, Sally, Lipson, David A., Lomas, David A., Martin, Neil, Martinez, Fernando J., Wise, Robert, Singh, Dave, Bafadhel, Mona, Barnes, Neil, Bourke, Stephen C., Compton, Chris, Criner, Gerard J., Dransfield, Mark T., Halpin, David M.G., Han, Mei Lan K., Hartley, Benjamin, Jones, C. Elaine, Lange, Peter, Lettis, Sally, Lipson, David A., Lomas, David A., Martin, Neil, Martinez, Fernando J., Wise, Robert, and Singh, Dave

Published
2021

208. Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries:Analysis of the IMPACT Trial

Author

Halpin, David M. G., Criner, Gerard J., Dransfield, Mark T., Han, MeiLan K., Hartley, Benjamin, Harvey, Catherine, Jones, C. Elaine, Kato, Motokazu, Lange, Peter, Lettis, Sally, Lomas, David A., Martinez, Fernando J., Martin, Neil, Singh, Dave, Wise, Robert, Zheng, Jinping, Lipson, David A., Halpin, David M. G., Criner, Gerard J., Dransfield, Mark T., Han, MeiLan K., Hartley, Benjamin, Harvey, Catherine, Jones, C. Elaine, Kato, Motokazu, Lange, Peter, Lettis, Sally, Lomas, David A., Martinez, Fernando J., Martin, Neil, Singh, Dave, Wise, Robert, Zheng, Jinping, and Lipson, David A.

Abstract

Introduction In the IMPACT trial, single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) reduced moderate/severe exacerbation rates versus FF/VI or UMEC/VI dual therapy in patients with chronic obstructive pulmonary disease (COPD); however, pneumonia incidence was higher in FF-containing arms. As COPD is a growing problem in Asia, we compared the efficacy and safety of FF/UMEC/VI in Asia versus non-Asia regions. Methods IMPACT was a double-blind, 52-week trial in symptomatic COPD patients with >= 1 moderate/severe exacerbation in the prior year. This pre-specified analysis evaluated the annual rate of moderate/severe exacerbations, change from baseline in trough forced expiratory volume in 1 s, and St George's Respiratory Questionnaire total score, mortality, and safety (including pneumonia) in Asia versus non-Asia regions. Results The intent-to-treat population comprised 10,355 patients (Asia n = 1644 [16%]). Rate ratios (95% confidence intervals) for moderate/severe exacerbations with FF/UMEC/VI were 0.89 (0.76-1.05) versus FF/VI and 0.86 (0.71-1.04) versus UMEC/VI in Asia, and 0.84 (0.79-0.90) and 0.74 (0.68-0.80) in non-Asia. Efficacy of FF/UMEC/VI on other endpoints was similar in both regions. There was an increased incidence of investigator-reported pneumonia in patients in Asia (FF/UMEC/VI: 13%; FF/VI: 14%; UMEC/VI: 6%) compared with non-Asia (FF/UMEC/VI: 6%; FF/VI: 5%; UMEC/VI: 4%). The increased risk of pneumonia in patients in Asia was most marked in patients with lower body mass index, lower lung function, and taking inhaled corticosteroids. In post hoc analysis of adjudicated on-treatment all-cause mortality, probabilities of death were numerically lower in both regions with FF/UMEC/VI (Asia: 1.16%; non-Asia: 1.35%) and FF/VI (Asia: 1.77%; non-Asia: 1.21%) versus UMEC/VI (Asia: 1.91%; non-Asia: 2.23%). Conclusions FF/UMEC/VI provides similar benefits in COPD patients in Asia and non-Asia regions. Clinical benefits o

Published
2021

209. Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT

Author

Dransfield, Mark T., Crim, Courtney, Criner, Gerard J., Day, Nicola C., Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kilbride, Sally, LaFon, David, Lipson, David A., Lomas, David A., Martin, Neil, Martinez, Fernando J., Singh, Dave, Wise, Robert A., Lange, Peter, Dransfield, Mark T., Crim, Courtney, Criner, Gerard J., Day, Nicola C., Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kilbride, Sally, LaFon, David, Lipson, David A., Lomas, David A., Martin, Neil, Martinez, Fernando J., Singh, Dave, Wise, Robert A., and Lange, Peter

Abstract

Rationale: In the IMPACT (Informing the Pathway of COPD Treatment) trial, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy reduced exacerbation risk versus FF/VI and UMEC/VI and mortality risk versus UMEC/VI. However, pneumonia incidence was higher in the inhaled corticosteroid (FF)containing arms, raising questions about the relative benefit of exacerbation reduction compared with the increased risk of pneumonia.Objectives: Determine benefit-risk of the three treatments by evaluating time-to-first and rates of composite exacerbation or pneumonia outcomes.Methods: We evaluated time-to-first (prespecified) and rates (post hoc) of investigator-reported pneumonia, serious pneumonia leading to hospitalization or death, and the composite endpoints of 1) moderate (required antibiotics/corticosteroids)/severe (hospitalized) exacerbation or pneumonia and 2) severe exacerbation or serious (hospitalized) pneumonia. Analyses were repeated for radiographically confirmed pneumonia (post hoc).Results: Moderate/severe exacerbations occurred in 47%, 49%, and 50% of patients randomized to FF/UMEC/VI, FF/VI andUMEC/VI, and pneumonias in 8%, 7%, and 5%, respectively. FF/UMEC/VI reduced the risk of combined moderate/severe exacerbation or pneumonia (time-to-first) versus FF/VI (hazard ratio, 0.87 [95% confidence interval (CI), 0.82-0.92]) and UMEC/VI (0.87 [0.81-0.94]), as well as the risk of combined severe exacerbation or serious pneumonia versus UMEC/VI (0.83 [0.72-0.96]). FF/UMEC/VI reduced the rate of combined moderate/severe exacerbation or pneumonia (rate ratio, 0.78 [0.72-0.84]) and combined severe exacerbation or serious pneumonia (rate ratio, 0.76 [0.65-0.89]) versus UMEC/VI. Results were similar for radiographically confirmed pneumonia endpoints.Conclusions: Despite higher incidence of pneumonia in FF-containing arms, these composite exacerbation/pneumonia outcomes support a favorable benefit-risk profile o

Published
2021

210. Prognostic value of clinically important deterioration in COPD:IMPACT trial analysis

Author

Han, MeiLan K., Criner, Gerard J., Dransfield, Mark T., Halpin, David M. G., Jones, Christine E., Kilbride, Sally, Lange, Peter, Lettis, Sally, Lipson, David A., Lomas, David A., Martin, Neil, Martinez, Fernando J., Wise, Robert A., Naya, Ian P., Singh, Dave, Han, MeiLan K., Criner, Gerard J., Dransfield, Mark T., Halpin, David M. G., Jones, Christine E., Kilbride, Sally, Lange, Peter, Lettis, Sally, Lipson, David A., Lomas, David A., Martin, Neil, Martinez, Fernando J., Wise, Robert A., Naya, Ian P., and Singh, Dave

Abstract

Introduction: Clinically important deterioration (CID) is a multicomponent measure for assessing disease worsening in chronic obstructive pulmonary disease (COPD). This analysis investigated the prognostic value of a CID event on future clinical outcomes and the effect of single-inhaler triple versus dual therapy on reducing CID risk in patients in the IMPACT trial.Methods: IMPACT was a phase III, double-blind, 52-week, multicentre trial. Patients with symptomatic COPD and at least one moderate/severe exacerbation in the prior year were randomised 2:2:1 to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mu g, FF/VI 100/25 mu g or UMEC/VI 62.5/25 mu g. CID at the time-point of interest was defined as a moderate/severe exacerbation, >= 100 mL decrease in trough forced expiratory volume in 1 s or deterioration in health status (increase of >= 4.0 units in St George's Respiratory Questionnaire total score or increase of >= 2.0 units in COPD Assessment Test score) from baseline. A treatment-independent post hoc prognostic analysis compared clinical outcomes up to week 52 in patients with/without a CID by week 28. A prospective analysis evaluated time to first CID with each treatment.Results: Patients with a CID by week 28 had significantly increased exacerbation rates after week 28, smaller improvements in lung function and health status at week 52 (all pConclusions: Prevention of short-term disease worsening was associated with better long-term clinical outcomes. FF/UMEC/VI reduced CID risk versus dual therapies; this effect may improve long-term prognosis in this population.

Published
2021

212. The challenge of addressing obesity in people with poorly controlled asthma

Author

Dixon, Anne E., primary, Blake, Kathryn V., additional, DiMango, Emily A., additional, Dransfield, Mark T., additional, Feemster, Laura C., additional, Johnson, Olivia, additional, Roy, Gem, additional, Hazucha, Heather, additional, Harvey, Jean, additional, McCormack, Meredith C., additional, Wise, Robert A., additional, and Holbrook, Janet T., additional

Published
2021
Full Text
View/download PDF

213. Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT

Author

Dransfield, Mark T., primary, Crim, Courtney, additional, Criner, Gerard J., additional, Day, Nicola C., additional, Halpin, David M. G., additional, Han, MeiLan K., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, LaFon, David, additional, Lipson, David A., additional, Lomas, David A., additional, Martin, Neil, additional, Martinez, Fernando J., additional, Singh, Dave, additional, Wise, Robert A., additional, and Lange, Peter, additional

Published
2021
Full Text
View/download PDF

219. Computed Tomographic Measures of Pulmonary Vascular Morphology in Smokers and Their Clinical Implications

Author

Estépar, Raúl San José, Kinney, Gregory L., Black-Shinn, Jennifer L., Bowler, Russell P., Kindlmann, Gordon L., Ross, James C., Kikinis, Ron, Han, MeiLan K., Come, Carolyn E., Diaz, Alejandro A., Cho, Michael H., Hersh, Craig P., Schroeder, Joyce D., Reilly, John J., Lynch, David A., Crapo, James D., Wells, Michael J., Dransfield, Mark T., Hokanson, John E., and Washko, George R.

Published
2013
Full Text
View/download PDF

223. Pulmonary Arterial Enlargement and Acute Exacerbations of COPD

Author

Wells, Michael J., Washko, George R., Han, MeiLan K., Abbas, Naseer, Nath, Hrudaya, Mamary, James A., Regan, Elizabeth, Bailey, William C., Martinez, Fernando J., Westfall, Elizabeth, Beaty, Terri H., Curran-Everett, Douglas, Curtis, Jeffrey L., Hokanson, John E., Lynch, David A., Make, Barry J., Crapo, James D., Silverman, Edwin K., Bowler, Russell P., and Dransfield, Mark T.

Published
2012
Full Text
View/download PDF

227. The presence of emphysema on chest imaging and mid-life cognition

Author

Henkle, Benjamin E., primary, Colangelo, Laura A., additional, Dransfield, Mark T., additional, Hou, Lifang, additional, Jacobs, David R., additional, Joyce, Brian T., additional, Pistenmaa, Carrie L., additional, Putman, Rachel K., additional, Sidney, Steve, additional, Thyagarajan, Bharat, additional, Washko, George R., additional, Yaffe, Kristine, additional, Kalhan, Ravi, additional, and Kunisaki, Ken M., additional

Published
2021
Full Text
View/download PDF

228. Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis

Author

Han, MeiLan K., primary, Criner, Gerard J., additional, Dransfield, Mark T., additional, Halpin, David M.G., additional, Jones, Christine E., additional, Kilbride, Sally, additional, Lange, Peter, additional, Lettis, Sally, additional, Lipson, David A., additional, Lomas, David A., additional, Martin, Neil, additional, Martinez, Fernando J., additional, Wise, Robert A., additional, Naya, Ian P., additional, and Singh, Dave, additional

Published
2021
Full Text
View/download PDF

229. Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study

Author

Fawzy, Ashraf, primary, Woo, Han, additional, Balasubramanian, Aparna, additional, Barjaktarevic,, Igor, additional, Barr, R. Graham, additional, Bowler, Russell P., additional, Comellas, Alejandro P., additional, Cooper, Christopher B., additional, Couper, David, additional, Criner, Gerard J., additional, Dransfield, Mark T., additional, Han, MeiLan K., additional, Hoffman, Eric A., additional, Kanner, Richard E., additional, Krishnan, Jerry A., additional, Martinez, Fernando J., additional, McCormack, Meredith, additional, Paine III, Robert, additional, Peters, Stephen, additional, Wise, Robert, additional, Woodruff, Prescott G., additional, Hansel, Nadia N., additional, and Putcha, Nirupama, additional

Published
2021
Full Text
View/download PDF

230. Azithromycin for Prevention of Exacerbations of COPD

Author

Albert, Richard K., Connett, John, Bailey, William C., Casaburi, Richard, Cooper, Allen J.D., Jr., Criner, Gerard J., Curtis, Jeffrey L., Dransfield, Mark T., Han, MeiLan K., Lazarus, Stephen C., Make, Barry, Marchetti, Nathaniel, Martinez, Fernando J., Madinger, Nancy E., McEvoy, Charlene, Niewoehner, Dennis E., Porsasz, Janos, Price, Connie S., Reilly, John, Scanlon, Paul D., Sciurba, Frank C., Scharf, Steven M., Washko, George R., Woodruff, Prescott G., and Anthonisen, Nicholas R.

Published
2011
Full Text
View/download PDF

231. Clinical Phenotypes of Atopy and Asthma in COPD

Author

Putcha, Nirupama, primary, Fawzy, Ashraf, additional, Matsui, Elizabeth C., additional, Liu, Mark C., additional, Bowler, Russ P., additional, Woodruff, Prescott G., additional, O’Neal, Wanda K., additional, Comellas, Alejandro P., additional, Han, MeiLan K., additional, Dransfield, Mark T., additional, Wells, J. Michael, additional, Lugogo, Njira, additional, Gao, Li, additional, Talbot, C. Conover, additional, Hoffman, Eric A., additional, Cooper, Christopher B., additional, Paulin, Laura M., additional, Kanner, Richard E., additional, Criner, Gerard, additional, Ortega, Victor E., additional, Barr, R. Graham, additional, Krishnan, Jerry A., additional, Martinez, Fernando J., additional, Drummond, M. Bradley, additional, Wise, Robert A., additional, Diette, Gregory B., additional, Hersh, Craig P., additional, and Hansel, Nadia N., additional

Published
2020
Full Text
View/download PDF

233. Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial

Author

Halpin, David M. G., primary, Criner, Gerard J., additional, Dransfield, Mark T., additional, Han, MeiLan K., additional, Hartley, Benjamin, additional, Harvey, Catherine, additional, Jones, C. Elaine, additional, Kato, Motokazu, additional, Lange, Peter, additional, Lettis, Sally, additional, Lomas, David A., additional, Martinez, Fernando J., additional, Martin, Neil, additional, Singh, Dave, additional, Wise, Robert, additional, Zheng, Jinping, additional, and Lipson, David A., additional

Published
2020
Full Text
View/download PDF

234. The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial

Author

Han, MeiLan K., primary, Criner, Gerard J., additional, Dransfield, Mark T., additional, Halpin, David M. G., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lettis, Sally, additional, Lipson, David A., additional, Lomas, David A., additional, Martin, Neil, additional, Wise, Robert A., additional, Singh, Dave, additional, and Martinez, Fernando J., additional

Published
2020
Full Text
View/download PDF

236. Clinical Investigator Training Program (CITP) – A practical and pragmatic approach to conveying clinical investigator competencies and training to busy clinicians

Author

Saleh, Mansoor, primary, Naik, Gurudatta, additional, Jester, Penelope, additional, Joiner, Cynthia, additional, Westfall, Elizabeth, additional, Kimberlin, David W., additional, Willig, James, additional, Redden, David, additional, Southworth, Juliette, additional, and Dransfield, Mark T., additional

Published
2020
Full Text
View/download PDF

239. Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the Spiromics Cohort

Author

Cooper, Christopher B, primary, Paine, Robert, additional, Curtis, Jeffrey L, additional, Kanner, Richard E, additional, Martinez, Carlos H, additional, Meldrum, Catherine A, additional, Bowler, Russell, additional, O'Neal, Wanda, additional, Hoffman, Eric A, additional, Couper, David, additional, Quibrera, Miguel, additional, Criner, Gerald, additional, Dransfield, Mark T, additional, Han, MeiLan K, additional, Hansel, Nadia N, additional, Krishnan, Jerry A, additional, Lazarus, Stephen C, additional, Peters, Stephen P, additional, Barr, R Graham, additional, Martinez, Fernando J, additional, and Woodruff, Prescott G, additional

Published
2020
Full Text
View/download PDF

240. Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study

Author

Tabberer, Maggie, primary, Jones, C. Elaine, additional, Kilbride, Sally, additional, Halpin, David M. G., additional, Lomas, David A., additional, Pascoe, Steven, additional, Singh, Dave, additional, Wise, Robert A., additional, Criner, Gerard J., additional, Lange, Peter, additional, Dransfield, Mark T., additional, Han, MeiLan K., additional, Martinez, Fernando J., additional, Kaisermann, Morrys C., additional, and Lipson, David A., additional

Published
2020
Full Text
View/download PDF

242. Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial

Author

Dransfield, Mark T., primary, Garner, Justin L., additional, Bhatt, Surya P., additional, Slebos, Dirk-Jan, additional, Klooster, Karin, additional, Sciurba, Frank C., additional, Shah, Pallav L., additional, Marchetti, Nathaniel T., additional, Sue, Richard D., additional, Wright, Shawn, additional, Rivas-Perez, Hiram, additional, Wiese, Tanya A., additional, Wahidi, Momen M., additional, Goulart de Oliveira, Hugo, additional, Armstrong, Brian, additional, Radhakrishnan, Sri, additional, Shargill, Narinder S., additional, Criner, Gerard J., additional, Katz, Lewis, additional, Cordova, Francis, additional, Desai, Parag, additional, Marchetti, Nathaniel, additional, Kim, Victor, additional, Shenoy, Kartik, additional, Travaline, John, additional, Thomas, Jiji, additional, Criner, Lii-Yoong H., additional, Sue, Richard, additional, Thornburg, Aaron, additional, Thomas, Terry, additional, Dransfield, Mark, additional, Bhatt, Surya, additional, Wells, James Michael, additional, Seabron-Harris, Necole, additional, Gauhar, Umair, additional, Despirito, Crissie, additional, Sciurba, Frank, additional, Bon Field, Jessica, additional, Chandra, Divay, additional, Leader, Joseph, additional, Semaan, Roy, additional, Ledezma, Christina, additional, Shah, Pallav, additional, Kemp, Samuel, additional, Garner, Justin, additional, Aboelhassan, Arafa, additional, Srikanthan, Karthi, additional, Tenda, Eric, additional, Abraham, Anita, additional, Sim, Cai, additional, Wahidi, Momen, additional, Mahmood, Kamran, additional, Shofer, Scott, additional, Coles, Kathleen, additional, de Oliveira, Hugo Goulart, additional, Oliveira, Guilherme Augusto, additional, Machado, Betina, additional, Benedetto, Igor, additional, Svartman, Fabio, additional, de Macedo Neto, Amarilio, additional, Schreiner, Leonardo, additional, Vieira, Taiane, additional, Morrissey, Brian, additional, Yoneda, Ken, additional, Tham, Tina, additional, Tompkins, Daniel, additional, Guerreiro Cardoso, Paulo F., additional, Athanazio, Rodrigo, additional, Nominando, Felipe, additional, Rached, Samia, additional, Cassimiro, Luciana, additional, Hays, Steven, additional, Seeley, Eric, additional, Shrestha, Pavan, additional, Dincheva, Gabriela R., additional, Majid, Adnan, additional, Alape-Moya, Daniel, additional, Parikh, Mihir, additional, Paton, Alichia, additional, Agnew, Alexis, additional, Pastis, Nicholas, additional, Strange, Charlie, additional, Beiko, Tatsiana, additional, Woodford, Danielle, additional, Blanton, Mary, additional, Kopas, Lisa, additional, Connolly, Timothy, additional, Santacruz, Jose Fernando, additional, Shah, Bhavin, additional, Vollenweider, Mark, additional, Herrera, Luis, additional, Khan, Rumi, additional, Sernulka, Kristine, additional, McFadden, P. Michael, additional, Barbers, Richard, additional, Hernandez, Michelle, additional, Machuzak, Michael, additional, Almeida, Francisco, additional, Cicenia, Joseph, additional, Gildea, Thomas, additional, Mehta, Atul, additional, Sethi, Sonali, additional, Meli, Yvonne, additional, Hsia, David, additional, Casaburi, Richard, additional, Stringer, William, additional, Diaz, Leticia, additional, Sung, Arthur, additional, Ramsey, Meghan, additional, Van Wert, Ryan, additional, Morris, Karen, additional, Jarad, Nabil, additional, Batchelor, Tim, additional, Sequeiros, Iara, additional, Tucker, Katy, additional, Kornaszweska, Malgorzata, additional, Fallouh, Hazem, additional, Sabit, Ramsey, additional, Naase, Hatam, additional, George, Joseph, additional, Salimian, Azin, additional, Dyer, Helen, additional, Hazelrigg, Stephen, additional, Adams, Kristal, additional, Bade, Karen, additional, Krishna, Ganesh, additional, Benn, Bryan S., additional, Canfield, Michelle, additional, Vetri Villalan, Sharmila, additional, Stewart, Travis, additional, n Slebos, Dirk-Ja, additional, ten Hacken, Nick H. T., additional, Hartman, Jorine, additional, and Augustijn, Sonja, additional

Published
2020
Full Text
View/download PDF

243. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

Author

Lipson, David A., primary, Crim, Courtney, additional, Criner, Gerard J., additional, Day, Nicola C., additional, Dransfield, Mark T., additional, Halpin, David M. G., additional, Han, MeiLan K., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lomas, David A., additional, Lettis, Sally, additional, Manchester, Pamela, additional, Martin, Neil, additional, Midwinter, Dawn, additional, Morris, Andrea, additional, Pascoe, Steven J., additional, Singh, Dave, additional, Wise, Robert A., additional, and Martinez, Fernando J., additional

Published
2020
Full Text
View/download PDF

245. Heme metabolism genes Downregulated in COPD Cachexia

Author

Wilson, Ava C., primary, Kumar, Preeti L., additional, Lee, Sool, additional, Parker, Margaret M., additional, Arora, Itika, additional, Morrow, Jarrett D., additional, Wouters, Emiel F. M., additional, Casaburi, Richard, additional, Rennard, Stephen I., additional, Lomas, David A., additional, Agusti, Alvar, additional, Tal-Singer, Ruth, additional, Dransfield, Mark T., additional, Wells, J. Michael, additional, Bhatt, Surya P., additional, Washko, George, additional, Thannickal, Victor J., additional, Tiwari, Hemant K., additional, Hersh, Craig P., additional, Castaldi, Peter J., additional, Silverman, Edwin K., additional, and McDonald, Merry-Lynn N., additional

Published
2020
Full Text
View/download PDF

247. The Association Between Neighborhood Socioeconomic Disadvantage and Chronic Obstructive Pulmonary Disease

Author

Galiatsatos, Panagis, primary, Woo, Han, additional, Paulin, Laura M, additional, Kind, Amy, additional, Putcha, Nirupama, additional, Gassett, Amanda J, additional, Cooper, Christopher B, additional, Dransfield, Mark T, additional, Parekh, Trisha M, additional, Oates, Gabriela R, additional, Barr, R Graham, additional, Comellas, Alejandro P, additional, Han, Meilan K, additional, Peters, Stephen P, additional, Krishnan, Jerry A, additional, Labaki, Wassim W, additional, McCormack, Meredith C, additional, Kaufman, Joel D, additional, and Hansel, Nadia N, additional

Published
2020
Full Text
View/download PDF

248. Clinical Development and Research Applications of the Chronic Obstructive Pulmonary Disease Assessment Test

Author

Müllerová, Hana, primary, Dransfield, Mark T., additional, Thomashow, Byron, additional, Jones, Paul W., additional, Rennard, Stephen, additional, Karlsson, Niklas, additional, Fageras, Malin, additional, Metzdorf, Norbert, additional, Petruzzelli, Stefano, additional, Rommes, Jean, additional, Sciurba, Frank C., additional, Tabberer, Maggie, additional, Merrill, Debora, additional, and Tal-Singer, Ruth, additional

Published
2020
Full Text
View/download PDF

249. The effect of exacerbation history on outcomes in the IMPACT trial

Author

Halpin, David M.G., primary, Dransfield, Mark T., additional, Han, MeiLan K., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lipson, David A., additional, Lomas, David A., additional, Martinez, Fernando J., additional, Pascoe, Steve, additional, Singh, Dave, additional, Wise, Robert, additional, and Criner, Gerard J., additional

Published
2020
Full Text
View/download PDF

250. Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD

Author

Burkes, Robert M., primary, Ceppe, Agathe S., additional, Doerschuk, Claire M., additional, Couper, David, additional, Hoffman, Eric A., additional, Comellas, Alejandro P., additional, Barr, R. Graham, additional, Krishnan, Jerry A., additional, Cooper, Christopher, additional, Labaki, Wassim W., additional, Ortega, Victor E., additional, Wells, J. Michael, additional, Criner, Gerard J., additional, Woodruff, Prescott G., additional, Bowler, Russell P., additional, Pirozzi, Cheryl S., additional, Hansel, Nadia N., additional, Wise, Robert A., additional, Brown, Todd T., additional, Drummond, M. Bradley, additional, Alexis, Neil E., additional, Anderson, Wayne H., additional, Arjomandi, Mehrdad, additional, Barjaktarevic, Igor, additional, Bateman, Lori A., additional, Bhatt, Surya P., additional, Bleecker, Eugene R., additional, Boucher, Richard C., additional, Christenson, Stephanie A., additional, Cooper, Christopher B., additional, Couper, David J., additional, Crystal, Ronald G., additional, Curtis, Jeffrey L., additional, Dransfield, Mark T., additional, Drummond, Brad, additional, Freeman, Christine M., additional, Galban, Craig, additional, Han, MeiLan K., additional, Hastie, Annette T., additional, Huang, Yvonne, additional, Kaner, Robert J., additional, Kanner, Richard E., additional, Kleerup, Eric C., additional, LaVange, Lisa M., additional, Lazarus, Stephen C., additional, Martinez, Fernando J., additional, Meyers, Deborah A., additional, Moore, Wendy C., additional, Newell, John D., additional, Paine, Robert, additional, Paulin, Laura, additional, Peters, Stephen P., additional, Pirozzi, Cheryl, additional, Putcha, Nirupama, additional, Oelsner, Elizabeth C., additional, O’Neal, Wanda K., additional, Raman, Sanjeev, additional, Rennard, Stephen I., additional, Tashkin, Donald P., additional, Postow, Lisa, additional, and Viviano, Lisa, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results